JPRN-UMIN000002434已完成3 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS - A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS
ational Cancer Institute of Canada0 个研究点目标入组 560 人开始时间: 2010年1月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 560
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 65years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with a history of other malignancies. Patients with a serious active infection at the time of randomization or other serious underlying medical conditions that would impair the ability of the patient to receive protocol treatment. Patients with any condition (e.g. psychological, geographical, etc.) that does not permit compliance with the protocol. Patients with known hypersensitivity to temozolomide or compounds with similar chemical composition to temozolomide. Patients who have had treatment with any investigational cancer drug prior to randomization.
研究者
相似试验
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATIONVERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSElderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are not deemed suitable by their treating physician to receive the standard radiotherapy regimen (60 Gy / 30 fractions over 6 weeks) in combination with temozolomide.MedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-001949-26-FREORTC European Organisation for Research and Treatment of Cancer560
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTS - NDElderly (>65 years of age) patients with newly diagnosed, and histopathologically confirmed, glioblastoma multiforme (GBM, WHO grade IV) , who have had prior surgery/biopsy at diagnosis and who are not deemed suitable by their treating physician to receive the standard radiotherapy regimen (60 Gy / 30 fractions over 6 weeks) in combination with temozolomide.MedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2008-001949-26-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER562
已完成
3 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSgrade IV brain tumor10029211glioblastomaNL-OMON39213European Organisation for Research in Treatment of Cancer (EORTC)45
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATIONVERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSEUCTR2008-001949-26-BEEORTC European Organisation for Research and Treatment of Cancer560
进行中（未招募）
1 期
A RANDOMIZED PHASE III STUDY OF TEMOZOLOMIDE AND SHORT-COURSE RADIATION VERSUS SHORT-COURSE RADIATION ALONE IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME IN ELDERLY PATIENTSEUCTR2008-001949-26-DEEORTC European Organisation for Research and Treatment of Cancer560